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Abstract
Background and objectives Cognitive impairment is a core symptom domain of schizophrenia, neurological
disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive
functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia
provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a
component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability
to improve cognitive impairment has not been thoroughly explored. The aim of this systematic review was to
evaluate preclinical and clinical literature on the effects of CBD in cognitive domains relevant to
schizophrenia. Methods A systematic literature search was performed across numerous electronic databases
for English language articles ( January 1990-March 2016), with 27 articles (18 preclinical and 9 clinical
studies) included in the present review. Results CBD improves cognition in multiple preclinical models of
cognitive impairment, including models of neuropsychiatric (schizophrenia), neurodegenerative (Alzheimer's
disease), neuro-inflammatory (meningitis, sepsis and cerebral malaria) and neurological disorders (hepatic
encephalopathy and brain ischemia). To date, there is one clinical investigation into the effects of CBD on
cognition in schizophrenia patients, with negative results for the Stroop test. CBD attenuates Δ9-THC-
induced cognitive deficits. Conclusions The efficacy of CBD to improve cognition in schizophrenia cannot be
elucidated due to lack of clinical evidence; however, given the ability of CBD to restore cognition in multiple
studies of impairment, further investigation into its efficacy in schizophrenia is warranted. Potential
mechanisms underlying the efficacy of CBD to improve cognition are discussed.
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Background and Objectives: Cognitive impairment is a core symptom domain of schizophrenia, neurological 32 
disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive 33 
functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide 34 
limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the 35 
cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve 36 
cognitive impairment has not been thoroughly explored. The aim of this systematic review was to evaluate 37 
preclinical and clinical literature on the effects of CBD in cognitive domains relevant to schizophrenia.  38 
Methods: A systematic literature search was performed across numerous electronic databases for English 39 
language articles (January 1990 to March 2016), with 27 articles (18 preclinical and 9 clinical studies) included 40 
in the present review.  41 
Results: CBD improves cognition in multiple preclinical models of cognitive impairment, including models of 42 
neuropsychiatric (schizophrenia), neurodegenerative (Alzheimer’s disease), neuro-inflammatory (meningitis, 43 
sepsis and cerebral malaria) and neurological disorders (hepatic encephalopathy and brain ischemia). To-date, 44 
there is one clinical investigation into the effects of CBD on cognition in schizophrenia patients, with negative 45 
results for the stroop test. CBD attenuates Δ9-THC-induced cognitive deficits.  46 
Conclusions: The efficacy of CBD to improve cognition in schizophrenia cannot be elucidated due to lack of 47 
clinical evidence; however, given the ability of CBD to restore cognition in multiple studies of impairment, 48 
further investigation into its efficacy in schizophrenia is warranted. Potential mechanisms underlying the 49 














1 Introduction 61 
Since the introduction of ‘third generation’ atypical antipsychotics in the 1990s, there have been relatively few 62 
clinically significant advances in treatment options for patients suffering from affective and non-affective 63 
psychotic disorders such as schizophrenia and bipolar disorder [1]. Antipsychotics have therapeutic efficacy in 64 
treating some of the positive (hallucinations, delusions) and negative (anhedonia, apathy) symptoms of 65 
schizophrenia; however, they are limited in their ability to treat the cognitive domain of the disease [2]. 66 
Cognitive impairment is a core symptom underlying many neuropsychiatric disorders. Approximately 75-85% 67 
of people with schizophrenia experience deficits in cognition that negatively impact day-to-day living, including 68 
the ability to maintain employment, relationships and self-care [3]. Cognitive deficits often precede the 69 
emergence of other symptoms in schizophrenia, are associated with poor medication compliance and a higher 70 
tendency for relapse in first episode psychosis [4]. In fact, cognitive deficits are considered a better prognostic 71 
indicator in schizophrenia patients than other symptom domains because the severity of cognitive dysfunction 72 
correlates with earlier disease onset [2] and can predict clinical course and future functional outcomes [5]. As 73 
current antipsychotic medications show minimal benefits for cognitive impairment [2] and have adverse side-74 
effects (such as weight gain and motor disturbances) [6], there is an urgent requirement to identify new 75 
pharmacological treatments that can enhance cognitive function and improve the overall quality of life for 76 
people with schizophrenia. In an effort to address cognitive dysfunction in schizophrenia, the Measurement and 77 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was developed that identifies 78 
7 primary cognitive domains as targets for treatment in schizophrenia [2]. These domains include processing 79 
speed, verbal learning and memory, attention and vigilance, reasoning and problem solving, visual learning and 80 
memory, social cognition and working memory [2]. The authors [2] recommend that preclinical studies 81 
assessing the efficacy and functional outcomes of new pharmacological treatments in schizophrenia models 82 
should use behavioural tests that examine domains identified in MATRICS. Likewise, the MATRICS 83 
Consensus Cognitive Battery (a battery of 10 tests that examine the MATRICs cognitive domains) should be 84 
used in clinical trials that assess the efficacy of potential cognitive-enhancing drugs for schizophrenia, to ensure 85 
standardised testing and maximise reproducibility between trials [2].  86 
 87 
Cannabis sativa is the most widely used drug in the world and contains over 70 different constituents, including 88 
delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) [7]. Compared to the general population, 89 




symptoms and a higher incidence of relapse and poor treatment outcomes in users [7]. Cannabis use during 91 
adolescence is a well-documented risk factor for developing schizophrenia and lowers the age of symptom onset 92 
[8]. Cannabis interacts with the endogenous cannabinoid system and alterations in endogenous cannabinoid 93 
signalling have been observed in patients with schizophrenia. For example, studies report elevated levels of the 94 
endogenous cannabinoids anandamide (AEA) and 2-arachidonyl glycerol (2-AG) in cerebrospinal fluid and 95 
blood samples of patients [9-13], while post-mortem brain tissue and neuroimaging studies report elevations in 96 
cannabinoid CB1 receptor density in brain regions implicated in cognition, in people with schizophrenia [14-97 
16]. Interestingly, ∆9-THC administration induces symptoms in healthy volunteers that resemble psychosis, 98 
including hallucinations, delusions, depersonalisation and emotional lability, coupled with cognitive impairment 99 
in learning and memory domains [7]. On the other hand, initial observations in the 1970s suggested that the 100 
cannabis constituent CBD interferes with the detrimental actions of Δ9-THC in terms of psychotic proneness and 101 
cognitive dysfunction [17]. Indeed, more recent studies have identified an inverse relationship between CBD 102 
content in cannabis strains and the prevalence of psychotic symptoms, such as hallucinations and delusions, 103 
suggesting a possible protective effect of CBD [18, 19]. Furthermore, clinical and preclinical studies spanning 104 
more than a decade [13, 20-23], demonstrate potential for CBD as an antipsychotic agent against the positive 105 
and negative symptoms of schizophrenia (as reviewed in [24]). Despite these findings, evidence of the efficacy 106 
of CBD to improve cognitive deficits associated with schizophrenia has not been thoroughly explored. CBD is a 107 
particularly interesting target as a novel approach to improving cognition in schizophrenia, in part, due to its 108 
strong anti-inflammatory properties [25]. Inflammation, particularly maternal immune activation during 109 
pregnancy, is a strong risk factor for schizophrenia pathogenesis and has been linked to the severity of cognitive 110 
deficits experienced by individuals [4]. Furthermore, immune system dysfunction has been reported in first 111 
episode and antipsychotic-treated schizophrenia patients, implicating this system in the pathogenesis of 112 
schizophrenia and as a potential therapeutic target for its treatment [4, 26].  113 
 114 
The aim of the present paper was to provide a detailed systematic literature review of existing preclinical and 115 
clinical research examining the effects of CBD on the cognitive domains relevant to schizophrenia, as identified 116 
by MATRICS [2]. Research papers included in this review were subdivided into the following categories: 1) 117 
studies that examined the ability of CBD to treat cognitive impairment in neuropsychiatric conditions and other 118 
neurological disorders, 2) studies that investigated the impact of CBD on cognitive measures during a cannabis 119 




based preclinical models of cognitive impairment. Finally, the potential mechanisms of CBD’s action on 121 
cognitive function, as well as recommendations for future research are discussed.  122 
 123 
2 Methods 124 
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews 125 
and Meta-Analyses (PRISMA) guidelines and reporting criteria [27]. The number of studies retained and 126 
omitted for this systematic review was recorded for each of the screening stages according to the PRISMA 127 
Statement (Figure 1) [27]. 128 
 129 
2.1 Search Strategy  130 
A literature search was performed using electronic databases (MEDLINE, Web of Science and Scopus) for 131 
original, published, English-language research articles, with publication dates spanning from January 1990 to 132 
March 2016. Key words included cannabidiol, cognition, cognitive impairment, memory and learning. Different 133 
combinations of search terms were used based on the requirements or limitations of each database. For example, 134 
the search strategy for Medline was (cannabidiol AND cognition) or (cannabidiol AND cognitive AND 135 
impairment).  The reference lists of eligible studies were also screened to identify additional studies. 136 
 137 
2.2 Eligibility Criteria 138 
Studies eligible for inclusion in this systematic review must have assessed the effect of CBD on cognitive 139 
domains relevant to schizophrenia (as defined in MATRICS) and must have been published in English. All 140 
studies were initially screened by title and abstract to ensure that only empirical studies related to the topic were 141 
included. Original research articles that passed the initial screening were reviewed in full text. Studies were 142 
further excluded that: (1) did not test cognitive domains related to MATRICS, used self-reporting measures to 143 
generate cognitive scores or focused on other outcomes (e.g. reward/motivation, anxiety), or (2) used 144 
standardised cannabis extracts containing both Δ9-THC and CBD, such as oromucosal sprays (Sativex®), 145 
without appropriate controls (i.e. Δ9-THC or CBD only groups) to assess the effects of CBD alone.  146 
 147 
2.3 Data Extraction and Analysis 148 
Following the screening process, original research articles that fit the criterion were further reviewed and the 149 




sample size, gender, drugs administered and dosage, as well as species and strain for preclinical studies. In 151 
addition, details of the CBD intervention were recorded, including the dose, frequency and route of 152 
administration, experimental paradigm used, as well as information pertaining to treatment outcomes, such as 153 
cognitive tests used (either clinical or behavioural), results of the cognitive testing, results of any biochemical 154 
analyses relating to cognition, and the overall conclusion of the research. The detailed information was tabulated 155 
and partitioned according to clinical or preclinical research (Tables 1 and 2, respectively).  156 
 157 
3 Literature Search Results  158 
The initial search strategy yielded a total of 75 articles from Medline (22 articles), Scopus (25 articles) and Web 159 
of Science (28 articles). Duplicate publications were excluded, yielding a total of 39 articles that were screened 160 
by title and abstract for eligibility. Nine studies were excluded because they did not use behavioural or clinical 161 
tests to assess cognition in the domains identified by MATRICS, they generated cognitive scores through self-162 
reported data or they did not report data from cognitive testing (Supplementary Table 1). Two studies 163 
investigating the effects of cannabis, and two studies investigating the effects of Sativex®, were excluded as 164 
they either lacked adequate control groups (either Δ9-THC or CBD only groups) to ascertain the effects of CBD 165 
alone, or did not report CBD content (Supplementary Table 1). A total of 27 studies passed the screening 166 
process and were collated for qualitative synthesis (Tables 1 and 2), including 9 clinical (human) studies 167 
(consisting of 1 double-blind, placebo-controlled trial; 1 randomised, double-blind, placebo-controlled trial; 1 168 
double-blind, placebo-controlled, cross-over trial; 4 randomised, double-blind, placebo-controlled, cross-over 169 
trials and 2 naturalistic, cross-over study designs) and 18 preclinical studies (including 11 mouse, 6 rat and 1 170 
non-human primate models). The clinical studies investigated the effects of CBD on: (1) verbal, episodic and 171 
recognition memory in cannabis users using naturalistic study designs (n=2); (2) working and social recognition 172 
memory, attention, verbal learning and memory and executive function using standardised cannabis extract or 173 
∆9-THC challenge paradigms in non-users and cannabis users (n=6); and (3) selective attention in schizophrenia 174 
patients (n=1). The preclinical studies included in this review investigated the effects of CBD on cognition in (1) 175 
neuropsychiatric modelling of schizophrenia and Alzheimer’s disease (n=6); (2) cannabis and ∆9-THC challenge 176 
paradigms and healthy rodents (n=4); (4) neurological conditions, such as brain ischemia, hepatic 177 
encephalopathy, as well as pain (n=5); and (4) inflammation-based models of cognitive impairment (n=3). 178 
Domains assessed by the preclinical studies aligned with the cognitive domains described in MATRICS and 179 




and declarative memory, and spatial learning and memory. In the present review, the literature pertaining to the 181 
effect of CBD on cognitive impairment in pathological states is presented separately to the literature examining 182 
the effects of CBD on cognition in drug-induced and healthy states.  183 
 184 
3.1 Cannabidiol as a therapeutic intervention for cognitive impairment in neuropsychiatric and 185 
neurodegenerative disorders  186 
3.1.1 Effects of CBD on cognitive function in schizophrenia 187 
There has been limited examination of the clinical efficacy of CBD to treat cognitive dysfunction in 188 
neuropsychiatric disorders, with one published study that examined effects in psychiatric patients [28] (Table 1) 189 
and two studies that utilised a preclinical model of schizophrenia in rodents [29, 30] (Table 2). A study 190 
conducted by Hallak et al [28] investigated the therapeutic efficacy of CBD to improve cognitive deficits in 191 
patients with schizophrenia. Testing comprised of two sessions, the first of which subjected participants to a 192 
Stroop Colour Word test, followed by a second session (one month later) where participants were administered a 193 
single dose of CBD (300 mg or 600 mg) or placebo then performed the Stroop Colour Word test one-hour post-194 
treatment, in order to assess the effects of CBD on selective attention [28]. The number of errors made in the 195 
Stroop Colour Word test significantly decreased between testing sessions in both the 300 mg CBD-treated and 196 
the placebo groups, with a similar trend observed in the 600 mg CBD-treated group [28]. The improvement 197 
across all experimental groups, particularly the placebo-treated group, is indicative of a learning effect rather 198 
than a treatment effect; the authors attributed the learning effect to the short (one month) between-test duration 199 
[28]. In addition, the lack of a control group (healthy volunteers) in the experimental design makes it difficult to 200 
determine if this cohort of individuals with schizophrenia had underlying selective attention deficits in 201 
comparison to the general population prior to the commencement of treatment. The only other studies to 202 
investigate the efficacy of CBD to treat cognitive deficits associated with schizophrenia were conducted in a 203 
preclinical schizophrenia model of N-methyl-D-aspartate (NMDA) receptor hypofunction, using the antagonist 204 
MK-801 [29, 30]. A study conducted by Deiana et al [29] administered CBD (5, 12 or 30 mg/kg) 30 minutes 205 
prior to MK-801 administration (0.08 mg/kg) and then tested social recognition memory in male Wistar rats. 206 
Acute pre-treatment with CBD did not prevent the MK-801-induced deficits in social recognition memory, 207 
while CBD administration to control rats had no significant effect on social recognition [29]. In another MK-801 208 
(1 mg/kg) study, mice were administered CBD for 22 days then subjected to the Novel Object Recognition 209 




total time spent exploring either the novel or familiar objects) was significantly higher in MK-801-treated mice 211 
administered 60 mg/kg CBD compared to controls, while 30 mg/kg CBD had no significant effect on the 212 
discrimination index [30]. As rodents have a natural tendency to explore novel objects, a reduction in the 213 
discrimination index demonstrates impaired object recognition memory [31]. Therefore, the results of these two 214 
studies suggest that high doses of CBD can alleviate object recognition memory dysfunction, but not social 215 
recognition memory in the MK-801 rodent model of schizophrenia. 216 
  217 
3.1.2 Effects of CBD on cognitive function in Alzheimer’s disease  218 
The therapeutic efficacy of CBD to treat cognitive deficits has also been examined in four studies using 219 
neurodegeneration rodent models of Alzheimer’s disease (AD) [32-35] (Table 2). A study conducted by Martin-220 
Moreno et al. [32] used intraventricular injection of β-amyloid (Aβ) to model AD, as Aβ plaque formation in the 221 
brain is a characteristic feature of AD pathogenesis. Aβ-injected mice displayed increased latency times to find a 222 
hidden platform in the Morris Water Maze, indicating impairment to spatial memory [32]. Conversely, Aβ-223 
injected mice administered CBD (20mg/kg) had latency times similar to controls, suggesting that CBD 224 
attenuates Aβ-induced deficits in spatial learning and memory [32]. Iron accumulation in the brain is also 225 
implicated in the pathogenesis of AD and administration of iron to rodents during the neonatal period mimics 226 
the persistent memory deficits observed in Alzheimer’s patients in the clinic [33]. Male rats subjected to iron-227 
overload during postnatal days 12-14 had a significantly lower recognition index during the NOR test compared 228 
control rats, indicating impaired recognition memory [33]. Acute CBD administration (10 mg/kg) significantly 229 
increased the recognition index of iron-overload rats compared to the vehicle controls, while chronic (2 weeks) 230 
CBD administration restored recognition memory in iron-overload rats in both the 5 mg/kg and 10 mg/kg 231 
dosage groups [33]. Two studies used a double transgenic mouse model of AD that co-expresses two of the 232 
three mutant genes implicated in familial AD pathogenesis, amyloid precursor protein (APP) and presenilin 1 233 
(PS1) [36], and exhibits accelerated amyloid pathology and deficits in object and social recognition memory 234 
[34, 35]. Chronic CBD administration (20 mg/kg) in APPxPSI mice significantly increased the time spent 235 
interacting with the novel object in the NOR test compared to vehicle-treated APPxPSI mice [34], 236 
demonstrating improved recognition memory in the CBD-treated mice. In the Social Preference test (which 237 
assesses social recognition memory based on the fact that rats prefer to interact with unfamiliar rats) all groups 238 
except the vehicle-treated APPxPSI mice demonstrated a preference for the novel rat, suggesting that CBD 239 




not affect associative learning in this mouse model of AD, as evidenced during the Fear Conditioning paradigm 241 
[34]. A subsequent long-term study (8 months) conducted by the same group investigated the ability of CBD to 242 
prevent cognitive deficits associated with AD using the double transgenic APPxPSI mouse model [35]. CBD 243 
(20 mg/kg) was administered daily for 8 months, after which time mice underwent a series of behavioural tests 244 
(Fear Conditioning Paradigm, Social Preference Test and the Elevated Plus Maze) [35]. The authors confirmed 245 
their previous finding of improved social recognition memory with chronic CBD administration, demonstrating 246 
that CBD is able to prevent the social recognition memory deficits of AD, but not associative learning deficits 247 
[35]. 248 
 249 
3.1.3 Conclusions 250 
The only clinical trial to investigate the efficacy of CBD to treat cognitive dysfunction in a neuropsychiatric 251 
disorder did not find any acute treatment effects of CBD on attention in the Stroop Colour Word test in 252 
schizophrenia patients [28]. On the other hand, the two preclinical reports showed that CBD attenuated object 253 
recognition memory deficits in an NMDA receptor hypofunction model of schizophrenia, with no effect on 254 
social recognition memory [29, 30]. Further research is required to investigate the potential of CBD to improve 255 
cognitive deficits in schizophrenia following a long-term CBD treatment period. In addition, to fully ascertain 256 
the potential benefits of CBD treatment on cognition in schizophrenia, further studies using tests that align with 257 
MATRICS are required. Several preclinical models demonstrate improved recognition, social recognition and 258 
spatial memory in AD paradigms following acute and chronic CBD treatment [32-35]. These results may have 259 
important implications for the treatment of neurodegenerative disorders; however, extensive randomised, 260 
controlled clinical trials are needed to confirm that findings translate to human patients.  261 
 262 
3.2 Effects of CBD on cognition in healthy and drug-induced states 263 
Eight studies explored the impact of CBD on cognitive function influenced by cannabis, while no studies have 264 
explored the effect of CBD on cognition in other drug-induced states (e.g. opioid, amphetamine, nicotine, 265 
alcohol). Two studies examined the influence of CBD on cognitive function in cannabis users during an 266 
intoxicated and un-intoxicated state (using their preferred cannabis strains) [37, 38] (Table 1), while 4 studies 267 
investigated the effects of CBD on cognitive function following Δ9-THC administration to human participants 268 
[39, 40] (Table 1), rats and monkeys [41, 42] (Table 2). Three studies examined the effect of CBD on cognition 269 




studies investigated the effect of CBD alone on cognitive function in healthy participants [46] (Table 1) and rats  271 
[47, 48] (Table 2).  272 
 273 
3.2.1 Effects of CBD on cognitive functioning in cannabis users 274 
The relative ratio of ∆9-THC and CBD varies greatly in cannabis strains, particularly with the introduction of 275 
high potency (high ∆9-THC) strains to the market, such as sinsemilla or ‘skunk’ (20% ∆9-THC: <0.5% CBD) 276 
that contain virtually no CBD (compared to previous strains that contained a 2:1 ratio of ∆9-THC:CBD) and are 277 
associated with a higher risk of psychosis [49]. Morgan et al [37] investigated the relationship between the CBD 278 
content of cannabis strains and cognitive functioning of users. Cannabis users were divided into two groups 279 
based on CBD content, ie: low (<0.14%) and high (>0.75%) CBD content groups (n=22 per group), based on 280 
sample analysis of the self-provided cannabis that participants smoked during this naturalistic study [37]. 281 
Participants were tested on verbal and category fluency, prose recall and source memory to assess verbal and 282 
episodic memory [37]. This cognitive testing was conducted on two separate occasions: in either drug-free or 283 
acutely intoxicated states. During acute intoxication, users of low CBD strains performed significantly worse in 284 
the Prose Recall Test compared to users of high CBD cannabis strains, while no changes were observed in 285 
Source Memory or Verbal and Category Fluency tests [37]. The cannabis sample analysis revealed no difference 286 
in ∆9-THC levels between the two groups; therefore, the results suggest that high cannabis CBD concentrations 287 
may be protective against ∆9-THC-induced verbal memory impairments. It is worth noting that the authors 288 
identified differences in other parameters between the high and low CBD cannabis groups, including higher 289 
alcohol consumption and lower Wechsler Adult Reading Test scores (reflecting reduced verbal memory ability) 290 
in the low CBD group; however, these factors were added as covariates in memory data analyses [37]. In 291 
addition, the authors suggested that differences in these other parameters were unlikely to explain the difference 292 
in verbal memory between the low and high CBD concentration groups during acute intoxication as 293 
performance did not differ between the low and high CBD groups during baseline (unintoxicated) testing [37]. 294 
In another study conducted by the same group, the relationship between cognitive function and the ratio of ∆9-295 
THC to CBD content in plant strains was examined in un-intoxicated chronic cannabis users [38]. Cannabis 296 
users were divided into two groups depending on the amount of cannabis they consumed i.e. recreational (n=54) 297 
or daily (n=66) users. Cognitive function was tested using Recognition Memory, Prose Recall and Source 298 
Memory tests. Additionally, participant hair samples were analysed for cannabinoid content [38]. The two 299 




who consumed cannabis strains containing CBD (as evidenced by the presence of CBD in the hair samples) 301 
displayed significantly better recognition memory compared to users who consumed cannabis strains with low 302 
CBD, regardless of the degree of cannabis use (daily or recreational) [38]. The presence or absence of CBD in 303 
hair samples did not influence Prose Recall or Source Memory test performance; however, when divided based 304 
on frequency of cannabis use, daily users of high ∆9-THC cannabis strains performed poorly in these tests 305 
compared to users of low ∆9-THC strains [38]. These results demonstrate that daily exposure to high ∆9-THC 306 
cannabis is associated with impaired verbal learning and memory, as well as episodic memory [38]. On the other 307 
hand, the presence of CBD in cannabis appears to protect against recognition memory impairment in 308 
unintoxicated, chronic daily and recreational cannabis users, but has no influence on verbal learning and 309 
memory, or episodic memory [38]. These naturalistic studies suggest that CBD may play a protective role in 310 
specific aspects of cannabis-induced cognitive impairment; however, considering the numerous constituents 311 
found in cannabis, it is difficult to conclude that any protective effects are wholly attributable to CBD.  312 
 313 
3.2.2 Effects of CBD on cognitive function in ∆9-THC administration studies 314 
The administration of ∆9-THC is a paradigm that allows investigation of CBD effects on cognition during an 315 
intoxicated state while removing the confounding factors associated with natural cannabis, including other 316 
cannabis constituents and differing CBD concentrations. For example, Hindocha et al [39] investigated the 317 
effects of ∆9-THC or CBD (administered independently or in combination) on emotional facial recognition in 318 
cannabis users with a diagnosis of schizotypy. Participants were divided into groups depending on the extent of 319 
cannabis use and schizotypy score (n=12 per group). Participants were randomised to receive ∆9-THC (8 mg), 320 
CBD (16 mg), ∆9-THC+CBD (8 mg+16 mg) or placebo over 4 drug sessions in a crossover design, with a one 321 
week washout period between each session [39]. Participants were presented with faces displaying varying 322 
emotional intensity (20-100%), including fearful, angry, happy, sad, surprise and disgust. As expected, the 323 
recognition of facial emotion became more accurate with increased intensity across all groups [39]. 324 
Administration of ∆9-THC significantly reduced performance in the Emotional Processing Task when subjects 325 
were presented with faces graded at 40% emotional intensity, while administration of CBD with ∆9-THC 326 
improved accuracy of emotion identification compared to the ∆9-THC only group [39]. Interestingly, CBD 327 
administration significantly improved accuracy in the emotional processing task beyond placebo levels [39]. 328 
There was no main effect of frequency of cannabis use or schizotypy diagnosis. Therefore, these results 329 




cannabis users, regardless of frequency of use or schizotypy score [39]. Another study conducted by Englund et 331 
al [40] directly tested the hypothesis that CBD prevents ∆9-THC-induced cognitive impairment by pre-treating 332 
healthy human participants with either CBD or placebo prior to receiving a ∆9-THC challenge (1.5 mg). CBD-333 
treated subjects performed better in delayed recall (during the Hopkins Verbal Learning Task Revised) 334 
compared to the placebo pre-treatment group, indicating that CBD treatment prevents verbal learning and 335 
memory deficits produced by ∆9-THC [40]. In the Digit Span Forward task, which assesses working memory, 336 
the placebo pre-treated group performed significantly worse following the ∆9-THC challenge compared to their 337 
corresponding baselines scores [40]. CBD pre-treatment resulted in similar scores to baseline (i.e. prior to the 338 
∆9-THC challenge), indicating that CBD limited the detrimental effects of ∆9-THC on working memory [40]. 339 
CBD pre-treatment was unable to prevent ∆9-THC-induced working memory impairment in the Digit Span 340 
Reverse task (also measures working memory), as performance was significantly worse in both groups 341 
following the ∆9-THC challenge (CBD and placebo pre-treatment), compared to baseline scores, possibly due to 342 
the increased difficulty of this test [40]. Overall, the findings of Englund et al [40] demonstrated that CBD pre-343 
treatment prevents ∆9-THC-induced deficits in verbal learning and memory, and specific (but not all) aspects of 344 
working memory in humans. A preclinical study conducted by Hayakaya et al [41] investigated treatment 345 
effects of various doses of CBD (3, 10 or 50 mg/kg) on cognition in ∆9-THC pre-treated (1 mg/kg) male mice. 346 
Pre-treatment with ∆9-THC impaired mouse performance in the Eight-arm Radial Maze, demonstrating impaired 347 
spatial learning and memory [41]. Low doses of CBD (3 mg/kg) restored performance in this test to control 348 
levels [41], demonstrating that CBD can improve ∆9-THC-induced deficits in spatial learning and memory. On 349 
the other hand, high doses of CBD (50 mg/kg) significantly increased the number of incorrect entries compared 350 
to vehicle administration following ∆9-THC pre-treatment. Interestingly, high doses of CBD administered alone 351 
did not impair performance in the Eight-arm Radial Maze, suggesting that CBD may potentiate the detrimental 352 
effects of ∆9-THC on spatial learning and memory when administered to mice at high doses [41]. Indeed, a 353 
previous study demonstrated that pre-treatment with high doses of CBD increased ∆9-THC concentrations in the 354 
blood and brain of rats [50], suggesting that a potential mechanism by which high dose CBD enhances ∆9-THC-355 
induced cognitive impairment may be through altered ∆9-THC metabolism. A study conducted by Wright et al 356 
[42] examined the effects of CBD on cognition in male Rhesus monkeys following acute ∆9-THC pre-treatment. 357 
The CBD/∆9-THC group performed significantly better on the Visuospatial Paired Associates Learning task, 358 
which assesses visual learning and memory, compared to the vehicle-treated ∆9-THC group [42]. In addition, 359 




[42]. Conversely, CBD did not improve the ∆9-THC-induced deficits in spatial working memory in the Self-361 
Ordered Spatial Search task. In fact, the CBD treatment group performed significantly worse compared to the 362 
control group (no ∆9-THC) [42].  363 
 364 
3.2.3 Effects of CBD on cognitive function using standardised cannabis extract 365 
The administration of standardised cannabis extracts (containing a defined ratio of ∆9-THC to CBD) with 366 
appropriate control groups (either ∆9-THC or CBD only groups) has also been employed as a paradigm that 367 
allows investigation of CBD treatment effects on cognition. For example, Roser et al [43] examined the effects 368 
of acute standardised cannabis extract (10 mg ∆9-THC+5.4 mg CBD) or ∆9-THC (10 mg) administration in 369 
healthy volunteers. Participants were asked to perform the Choice Reaction task, which assesses selective 370 
attention, while the amplitudes of auditory P300 event-related potentials were observed. In this paradigm, a 371 
sequence of repetitive tones was randomly interrupted by a tone with a different frequency, to elicit an auditory 372 
evoked P300 wave, a cognitive event-related potential (i.e. an electrophysiological response) that is measurable 373 
using electroencephalography (EEG). Reduced amplitudes of P300 waves are consistently found in 374 
schizophrenia patients, indicating deficient attention and working memory [43]. Reaction times in the Choice 375 
Reaction task did not differ between the cannabis extract and ∆9-THC groups; however, both the cannabis 376 
extract and ∆9-THC only groups displayed reduced P300 wave amplitudes compared to the placebo group, 377 
indicating that CBD was not able to attenuate deficits induced by ∆9-THC in this paradigm [43]. In another 378 
study, Schoedel et al [44] investigated the effects of the oromucosal spray Sativex® (GW Pharmaceuticals Ltd. 379 
Salisbury, UK) and dronabinol (synthetic THC: Marinol, Solvay Pharmaceuticals, Brussels, Belgium) on the 380 
cognitive performance of recreational cannabis users. Participants were administered Sativex® of varying doses 381 
(10.8 mg ∆9-THC+10 mg CBD; 21.6 mg ∆9-THC+20 mg CBD; and 43.2 mg ∆9-THC+40 mg CBD), or 382 
dronabinol (20 mg and 40 mg ∆9-THC), or placebo (control) and asked to perform several tests of attention and 383 
working memory (Choice Reaction Time task, Divided Attention test and the Short-Term Memory test) [44]. No 384 
significant effects of treatment were observed in the Choice Reaction Time or Divided Attention tasks; however, 385 
high dose dronabinol (40 mg) significantly increased Short-Term Memory test reaction time compared to the 386 
placebo [44]. This result was not observed with Sativex® containing both ∆9-THC and CBD suggesting that 387 
CBD attenuated the detrimental effect of high dose ∆9-THC on working memory performance in that study [44]. 388 
Further evidence that cannabis medicinal extracts do not impair cognition was reported by Wade et al [45], who 389 




multiple sclerosis patients did not affect their performance on the Short Orientation Memory Concentration 391 
(SOMC) test compared to placebo, while administration of ∆9-THC (2.5 mg) alone did impair performance.  392 
 393 
3.2.4 Effects of CBD alone on cognitive function in healthy models 394 
A study conducted by Bhattacharyya et al [46] investigated the effects of ∆9-THC (10 mg), CBD (600 mg) or 395 
placebo on brain activity using neuroimaging techniques (functional magnetic resonance imaging, fMRI) in 396 
healthy volunteers while performing cognitive tasks (Verbal Memory task to assess verbal learning and 397 
memory, Viewing Fearful Faces task to assess social recognition and Response Inhibition tasks to assess 398 
executive function). Interestingly, neither ∆9-THC nor CBD had any effect on cognitive task performance 399 
compared to the placebo [46]; a result that coincides with observations in healthy male Sprague-Dawley rats 400 
where acute CBD administration had no effect on spatial learning and memory in the Eight-arm Radial Maze 401 
[47]. In addition, Ward et al [48] found that acute CBD administration (2, 5 or 20 mg/kg) to female C57Bl mice 402 
30 minutes prior to performing an AutoShaping task had no effect on conditioned learning. Contrary to the lack 403 
of change in behavioural data reported by Bhattacharyya et al [46], they reported also that ∆9-THC and CBD 404 
had opposite effects on regional brain activation while the tasks were being performed [46]. In contrast to ∆9-405 
THC, CBD augmented striatal, anterior cingulate, medial and lateral prefrontal cortical activation during the 406 
Verbal Memory task. CBD also increased activation in the parahippocampal gyrus, left insula and caudate 407 
nucleus during the Response Inhibition task, while ∆9-THC attenuated activity relative to the placebo [46]. In 408 
the Viewing Fearful Faces task, CBD attenuated amygdala activation, which the authors suggest may be due to 409 
the anxiolytic properties of CBD [46]. While the 600 mg dose of CBD that was utilised by Bhattacharyya et al 410 
[46] had no apparent effect on cognition in healthy volunteers, it is interesting to note the contrasting brain 411 
region activation observed between the CBD and ∆9-THC treatment groups and further investigation into the 412 
functional implications of the result are warranted.  413 
 414 
3.2.5 Conclusions 415 
There is a disparity between studies investigating the effects of CBD on cognitive performance in cannabis users 416 
in an intoxicated state and following ∆9-THC challenge. In cannabis-induced cognitive impairment, CBD 417 
attenuates deficits in episodic and recognition memory, and verbal learning and memory; however, these 418 
beneficial effects vary depending on the duration (acute use vs. chronic use) and frequency (recreational vs. 419 




learning and memory, and procedural learning performance [42], while preventing ∆9-THC-induced 421 
impairments to verbal learning and memory, and improve some working memory tasks during a ∆9-THC 422 
challenge [40], with no effect on spatial learning and memory during ∆9-THC challenge [41]. In contrast, studies 423 
investigating the effects of standardised cannabis extracts found no significant effect of CBD on cognitive 424 
performance [43, 44], demonstrating that the one-to-one ratio of ∆9-THC to CBD has no detrimental effects on 425 
cognition [44]. In addition, pure CBD administered to healthy human participants and rats has no effect on 426 
cognition [46-48]. There is some crossover in cognitive improvements between human cannabis and ∆9-THC 427 
challenge studies; however, inconsistencies in dosage between these studies pose difficulties in direct 428 
comparison of treatment effects. On that note, it is important to consider dosage differences between these 429 
studies, i.e. the ratio of CBD to ∆9-THC in the ∆9-THC challenge studies in humans (16 mg CBD: 8 mg ∆9-430 
THC) differed to the ratios in Cannabis sativa strains (1.5% CBD: 12-18% ∆9-THC) [49]. The levels of ∆9-THC 431 
used to induce cognitive impairment (preclinical: 0.5, 1.0 mg/kg; clinical: 1.5 mg and a higher dose of 8 mg) 432 
and the dose of CBD used in clinical (16 mg and 600 mg) and preclinical studies (0.5, 1, 3, 10 and 50 mg/kg) 433 
varied. Future preclinical studies investigating the effects of CBD treatment should consider the translation of 434 
CBD doses in animals to human doses, as low doses of CBD in mice had beneficial effects on cognition, whilst 435 
high CBD doses enhanced the detrimental effects of ∆9-THC on cognition, possibly by impairing ∆9-THC 436 
clearance [41]. The bioavailability, peak concentrations and behavioural effects of cannabinoids vary depending 437 
on the route of administration [51], which also differed between the studies reviewed in this section (∆9-THC 438 
and CBD were administered orally [40, 43-46] or inhaled [39] in the clinical studies, while the preclinical 439 
studies used intramuscular [42] and intraperitoneal injections [47, 48]). Therefore, due to the differences in dose 440 
and route of administration, it is difficult to draw comparisons between the studies. Finally, although CBD is the 441 
main non-intoxicating component of cannabis, the plant contains over 70 different cannabinoids and, therefore, 442 
only associations can be drawn from studies investigating the effects of cannabis on cognition. Overall, further 443 
research is required to elucidate the therapeutic benefits of CBD on cognitive impairment in cannabis users and 444 
following ∆9-THC administration in healthy participants.   445 
 446 
3.3 Cannabidiol as a therapeutic intervention for cognitive impairment in neurological disorders  447 
3.3.1 Effects of CBD on cognitive functioning in preclinical brain ischemia models  448 
Two studies have investigated the effects of CBD on cognitive impairment in preclinical models of brain 449 




damage and apoptosis that result in impaired memory, attention and executive functioning [52, 53]. A study 451 
conducted by Pazos et al. [52] investigated the effects of CBD administration on cognition in Wistar rats 452 
exposed to hypoxic-ischemic (HI) brain injury after birth, modelled using left common carotid artery 453 
electrocoagulation techniques. Rats were administered a single subcutaneous injection of either CBD (1 mg/kg) 454 
10 minutes post-HI induction and were subjected to the NOR test. Vehicle-treated HI rats had less preference 455 
for the novel object compared to non-HI (sham) rats [52], indicating impairment to recognition memory in the 456 
model. Interestingly, CBD administration attenuated this deficit, returning novel object preference to control 457 
(sham) levels [52]. Spatial learning and memory deficits were observed in a similar model of brain ischemia in 458 
adult rodents [53]. In a study by Schiavon et al [53], groups of mice were administered either CBD (3, 10 or 30 459 
mg/kg) or vehicle, 30 minutes prior to a bilateral common carotid artery occlusion to induce brain ischemia (or 460 
sham surgery for controls). Mice were then treated again with CBD or vehicle 3, 24 and 48 hours post-surgery, 461 
and then underwent a Morris Water maze test one-week post-surgery to examine treatment effects on spatial and 462 
memory performance [53]. Vehicle-treated ischemic mice took longer to find the submerged platform than 463 
control mice, indicating impaired spatial learning and memory in the ischemia model [53]. On the other hand, 464 
mice treated with CBD (pre- and post-surgery 3, 10, or 30 mg/kg) had a lower latency to find the platform than 465 
vehicle-treated ischemic mice, indicating that CBD prevented the spatial learning and memory deficits induced 466 
by ischemia [53]. Taking both ischemia model studies into consideration, CBD appears to have a 467 
neuroprotective role and is able to both attenuate and prevent the learning and memory deficits induced by brain 468 
hypoxia.  469 
 470 
3.3.2 Effects of CBD on cognitive functioning in preclinical hepatic encephalopathy models  471 
Hepatic encephalopathy (HE) is a disorder that occurs due to build-up of toxic substances in the bloodstream 472 
during acute and chronic liver failure. HE manifests symptoms such as personality disturbances, impairments to 473 
muscular co-ordination, attention and other cognitive deficits [54-56]. In rodents, exposure to the hepatotoxin 474 
thioacetamide (TAA) is used to model acute HE [54], while chronic HE is induced by bile duct ligation (BDL) 475 
[55, 56]. Three preclinical studies involving HE modelling of cognitive impairment were identified during the 476 
literature search. In one study, acute CBD administration (5 mg/kg) improved the performance of TAA mice 477 
compared to vehicle-treated TAA mice in the eight-arm maze test, a measure of spatial learning and memory 478 
[54]. Another two studies investigated the effects of chronic CBD administration at the same dose (5mg/kg) 479 




significantly higher percentage of entries in the Eight-Arm Radial Maze compared to sham-treated mice 3 weeks 481 
post-surgery, demonstrating spatial learning and memory impairment in this model [55, 56]. Following 4 weeks 482 
of CBD treatment, CBD-treated BDL mice had a lower percentage of errors compared to vehicle-treated BDL 483 
mice, indicating that chronic CBD administration improves spatial learning and memory in this model [55, 56]. 484 
Likewise, BDL mice performed significantly worse in the T-Maze test compared to the Sham group, while CBD 485 
administration increased the number of entries, suggesting improved working memory by CBD in BDL mice 486 
[55]. Overall, these results suggest that chronic CBD treatment can attenuate working memory deficits, while 487 
improving spatial learning and memory with both acute and chronic treatment in a HE model.  488 
 489 
3.3.3 Conclusions  490 
The effect of CBD on cognitive function in neurological disorders has been investigated in preclinical models of 491 
brain ischemia and HE. Acute CBD administration improved recognition memory following impairment due to 492 
brain ischemia and prevented spatial learning and memory deficits [52, 53]. Acute and chronic CBD 493 
administration improved the spatial learning and memory, and working memory deficits induced by HE [54-56]. 494 
The evidence investigating the efficacy of CBD to treat cognitive impairment in neurological disorders is 495 
limited and further investigation of the apparent neuroprotective effect of CBD is warranted.  496 
 497 
3.4 Cannabidiol as a therapeutic intervention in inflammation-based models of cognitive impairment 498 
The link between the immune system and cognition has been well established [4, 57] as inflammatory states, 499 
including increased pro-inflammatory signalling, have been linked to cognitive dysfunction [4]. In healthy 500 
people, increased levels of pro-inflammatory cytokines (small molecules involved in immune system signalling) 501 
have been associated with poor performance in tasks that assess recognition and working memory, attention and 502 
executive function; cognitive domains that are affected in schizophrenia [58, 59]. In the current review, three 503 
preclinical studies investigated the effect of CBD on cognition using inflammation-based models [60-62] (Table 504 
2). One study used cecal ligation and puncture (CLP) as a model of systemic inflammatory disease (sepsis) that 505 
leads to neurological abnormalities including disorientation, lethargy, confusion and coma [60]. The authors 506 
assessed the effect of acute and sub-chronic CBD administration on cognitive function and oxidative parameters 507 
in male Wistar rats following CLP induction [60]. In the first experiment, rats received an acute injection of 508 
CBD (2.5, 5 or 10 mg/kg) immediately after CLP and were sacrificed after 6 hours [60]. In the second 509 




induction and were subjected to the Inhibitory Avoidance task, which measures associative learning [60]. Both 511 
the vehicle-treated sham rats and CBD-treated CLP rats improved performance between training and test 512 
sessions demonstrating a positive learning and memory effect; however, no significant difference was observed 513 
in vehicle-treated CLP rats, indicating memory impairment due to sepsis [60]. The improvement in associative 514 
learning by CBD treatment was evident not only at the same effective dose used in the HE models (5 mg/kg) 515 
[54-56], but also at lower (2.5 mg/kg) and higher (10 mg/kg) doses of CBD. Overall, these results suggest that 516 
sub-chronic CBD administration can attenuate the associative learning deficits produced in the CLP-induced 517 
sepsis model over a range of doses.  518 
 519 
In a study conducted by Barichello et al [61], male Wistar rats were administered a S.pneumoniae injection, 520 
which is used to model pneumococcal meningitis. Approximately one third of survivors of pneumococcal 521 
meningitis infection present with long-term cognitive impairment, including poor performance in memory tasks 522 
and generalised ‘cognitive slowing’ [63], possibly due to the infiltration of pro-inflammatory molecules in the 523 
brain [61]. Following pneumococcal meningitis induction, rats displayed impaired associative learning in the 524 
Inhibitory Avoidance task, a result that was not apparent in the sham treatment group. Importantly, sub-chronic 525 
(9 days) CBD administration (10 mg/kg, but not 2.5 or 5 mg/kg) restored associative learning in the 526 
pneumococcal meningitis model of cognitive impairment [61]. Therefore, similar to the CLP-induced sepsis 527 
model, sub-chronic administration of CBD can also attenuate the deficits in associative learning produced by 528 
pneumococcal meningitis. Campos et al [62] induced cerebral malaria in mice using Plasmodium berghei-529 
ANKA (PbA) infection. Cerebral malaria manifests as seizures, headache, severe cognitive impairment and 530 
often results in death in humans [62]. Three days post infection mice were administered CBD (30 mg/kg) or 531 
vehicle, followed by treatment with the anti-malarial drug, Artesunate, at the peak of the infection (5 days post 532 
infection) [62]. Behavioural testing 5 days post-infection showed that vehicle-treated PbA/Artesunate mice 533 
performed significantly worse on the NOR test and Morris Water maze, demonstrating persistent recognition 534 
and spatial memory impairments following malaria treatment [62]. On the contrary, PbA/Artesunate mice 535 
treated with CBD performed the memory tasks at control levels, indicating that CBD prevents PbA-induced 536 
cognitive deficits [62]. Based on these results, the authors suggested that CBD may be a potential adjunctive 537 
therapy for the treatment and/or prevention of the neurological deficits that result from cerebral malaria.  538 
 539 




Overall, inflammatory-based models of cognitive impairment consistently show that short-term and long-term 541 
CBD administration can attenuate deficits in spatial learning and memory, recognition memory and associative 542 
learning [60-62], which are cognitive domains affected in schizophrenia, as identified by MATRICS [2]. Given 543 
that CBD can improve cognition in preclinical models of inflammation-induced cognitive dysfunction it is 544 
reasonable to speculate that CBD may improve cognition in preclinical models of schizophrenia, particularly as 545 
growing evidence suggests an underlying immune dysfunction in the pathogenesis of this disorder [4].  546 
 547 
4 Potential mechanisms underlying CBD’s effects on cognition  548 
The present literature review provides the first systematic analysis of the available clinical and preclinical 549 
evidence on the effects of CBD on cognitive function. The limited evidence investigating the impact of CBD on 550 
cognitive deficits in neuropsychiatric disorders showed that CBD had no effect on selective attention in 551 
schizophrenia outpatients [28], while CBD administration attenuated object recognition memory impairment 552 
[30], but was unable to prevent social recognition memory deficits induced by MK-801 administration in 553 
rodents [29]. In preclinical models of AD, CBD treatment improved social and object recognition memory, with 554 
no effect on associative learning [32-35]. No human clinical evidence of CBD treatment effects on cognition in 555 
AD could be located during this literature search. The limited studies conducted in neurological disorders 556 
suggest that CBD has therapeutic benefits for spatial learning and memory, and recognition memory deficits 557 
induced by hypoxic brain injury [52, 53]. In preclinical models of hepatic encephalopathy, acute and chronic 558 
CBD administration improved spatial learning and memory, and working memory impairments [54-56]. CBD 559 
administration improved learning and memory function in preclinical models of inflammatory disorders such as 560 
sepsis [60], pneumococcal meningitis infection [61] and cerebral malaria [62]. In cannabis users, exposure to 561 
CBD attenuated episodic and recognition memory, and verbal learning and memory deficits; however, these 562 
beneficial effects varied depending on the duration and frequency of cannabis use [37, 38]. In ∆9-THC challenge 563 
studies, CBD intervention showed improvement in several cognitive domains (visual learning and memory, 564 
procedural learning, verbal learning and memory, and working memory tasks) [40, 42]. CBD dosage is 565 
particularly important to consider for ∆9-THC paradigms as low dose CBD had no effect on spatial learning and 566 
memory, while high CBD doses potentiated the detrimental effects of ∆9-THC [41]. Some studies using 567 
standardised cannabis extracts showed that CBD limited the detrimental effects of ∆9-THC on cognitive 568 
function [44, 45], while another study reported contrary findings of no effect [43]. Overall, CBD administration 569 




pathological and drug-induced states (i.e. healthy humans and animals) [46-48]. The neurobiology of cognition 571 
itself is not yet fully understood, but a vast body of evidence demonstrates the involvement of multiple neural 572 
networks with complex interactions between various signalling systems [3, 64]. Therefore, it is highly unlikely 573 
that CBD’s mechanism of action can be wholly attributed to one specific signalling pathway or system. Indeed, 574 
the preclinical studies included in this review demonstrate changes in multiple biochemical parameters; such as 575 
inflammatory and oxidative stress markers, as well as serotonin and adenosine neurotransmitter signalling, 576 
following CBD treatment of cognitive impairment. The role of these systems in the potential mechanisms 577 
underlying the effect of CBD on cognitive function is discussed below.  578 
 579 
4.1 Effects of CBD on neuroinflammatory markers 580 
Preclinical models of cognitive impairment (see Sections 3.1 to 3.3 of this review) showed that CBD treated 581 
cognitive dysfunction in areas of working and recognition memory, associative and spatial learning and 582 
memory, and social recognition memory [30, 32-35, 53-56, 60-62]. A number of these preclinical studies also 583 
assessed neuroinflammatory markers, including cytokine levels and expression, microglial activation and 584 
astrogliosis [32, 55, 56, 61].  Signalling of the pro-inflammatory cytokine, tumour necrosis factor-alpha (TNF-α) 585 
was significantly increased in the hippocampus and frontal cortex of preclinical models that exhibited HE or 586 
AD-induced spatial learning and memory, working memory and associative learning impairments [32, 55, 56, 587 
61]. Improved spatial learning and memory, as well as working memory following CBD administration has been 588 
associated with down-regulated hippocampal TNF-α and tumour necrosis factor-alpha receptor 1 (TNFRSF1) 589 
mRNA expression, with no change in cortical expression [32, 55, 56]. On the other hand, another study reported 590 
down-regulated TNF-α levels in the frontal cortex but not in the hippocampus following CBD administration 591 
and improved associative learning [61]. Conversely, cortical TNF-α mRNA expression did not change in AD 592 
rats exhibiting CBD-induced social recognition memory improvements [35]. Therefore, the literature is 593 
confounding but does suggest a possible involvement of TNF-α and TNFRSF1 signalling in the mechanisms 594 
underlying the ability of CBD to improve specific aspects of cognition. In addition, one study reported that 595 
expression of the pro-inflammatory cytokine interleukin-6 (IL-6) in the cerebral cortex was not altered by CBD 596 
treatment, suggesting that the spatial learning and memory improvements observed in the AD model may not be 597 
related to changes in IL-6 signalling [32]. Overall, caution may prudent when interpreting the TNF-α and IL-6 598 
results as these studies did not examine both protein and mRNA expression levels, which is important because 599 




to elucidate the role of pro-inflammatory cytokines in the improvement of cognition following CBD treatment, 601 
further studies investigating protein and mRNA expression, as well as receptor and downstream signalling 602 
pathways in brain regions relevant to the domains assessed by cognitive testing is required.  603 
 604 
Studies presented in this review have also investigated the reactivity of immune cells in the brain (such as 605 
microglia and astrocytes) in an effort to explain the mechanism of CBD’s apparent therapeutic effects on 606 
cognitive impairment. In neuroinflammatory states, activation of these immune cells leads to the release of pro-607 
inflammatory cytokines that can ultimately result in neuronal cell death [66]. Several preclinical models of 608 
cognitive impairment discussed in this review exhibit altered astrocyte and microglial activation [30, 53, 54]. 609 
For example, in the model of brain ischemia an increased number of active astrocytes was observed [54], while 610 
CBD treatment reduced the number of activated astrocytes. This finding was observed using glial fibrillary 611 
acidic protein (GFAP) immunohistochemistry methods to measure reactive astrogliosis (an abnormal increase in 612 
astrocytes in response to neuronal death), whereby the number of GFAP-positive cells provided an index of 613 
neuroinflammation [54]. Therefore, these results demonstrate that CBD treatment reduces neuroinflammation in 614 
this preclinical model of brain ischemia. Astrogliosis was also observed in the MK-801 model of schizophrenia; 615 
however, there was no effect of CBD treatment on GFAP-positive cell number indicating that CBD did not 616 
attenuate astrogliosis [30]. On the other hand, increased expression of the microglial activation marker, Iba 1, 617 
was observed in MK-801-treated rats, while CBD treatment attenuated microglial activation in the medial 618 
prefrontal cortex and CA1 region of the hippocampus, but not in the dentate gyrus [30]. Overall, the results from 619 
these studies imply that decreasing the pro-inflammatory immune response may serve as a potential mechanism 620 
by which CBD treatment restores cognitive function in pathological states. Considering the robust anti-621 
inflammatory properties of CBD [67], and the evidence that inflammation is implicated in cognitive deficits (as 622 
reviewed in [4]), more research along this line of investigation seems imperative. 623 
 624 
4.2 Effects of CBD on oxidative stress parameters 625 
Two studies included in the present review investigated the link between oxidative stress and cognitive 626 
performance [35, 60]. Oxidative damage to lipids was present in the striatum of cognitively impaired CLP 627 
(sepsis) rats, which was determined by measuring the levels of thiobarbituric acid reactive substances (TBARS, 628 
a by-product of lipid peroxidation and indicator of oxidative stress) [60]. Striatal TBARS levels were attenuated 629 




induced lipid oxidative damage and decreased protein carbonyl levels (an indicator of protein damage) 631 
compared to controls [60]. In contrast, another study found no change in the oxidative stress marker, F2-632 
isoprostanes, in the hippocampus following long-term CBD administration in a double transgenic mouse model 633 
of AD [35]. Overall, these studies suggest a specific effect of CBD on oxidative stress parameters in brain 634 
regions implicated in learning and memory; however, the results seem dependent on the pathological state and 635 
the oxidative stress marker measured.  636 
 637 
4.3 Effects of CBD on neurogenesis and neurotransmission 638 
In addition to increased pro-inflammatory signalling (see Section 4.1.1), a decrease in protein levels and gene 639 
expression of brain-derived neurotrophic factor (BDNF), a neurotrophic factor critical for learning and memory, 640 
was observed in preclinical models of HE and meningitis [55, 56, 61]. BDNF plays an important role in the 641 
maintenance and survival of neurons, as well as the growth and differentiation of new neurons and synapses. 642 
CBD administration significantly increased hippocampal BDNF mRNA expression in the HE model [55, 56]. 643 
Hippocampal BDNF levels were not affected by induced meningitis; however, levels in the frontal cortex were 644 
decreased and this deficit was restored by CBD treatment [38]. Immunohistochemistry and immunofluorescence 645 
techniques have confirmed an increase in hippocampal neurogenesis following CBD administration in a rat 646 
model of AD [68]. Therefore, these studies suggest that CBD may promote neurogenesis by increasing BDNF 647 
levels, changes in which may correlate with improved functional outcomes in cognition; however, further 648 
studies are required to confirm.   649 
 650 
Several studies presented in this review have also investigated the effects of CBD on serotonin and adenosine 651 
signalling, due to the role of these neurotransmitters in cognition and inflammation [54-56]. The adenosine A2 652 
receptor (A2AA-R) mediates the effects of BDNF on long-term potentiation and synaptic transmission [55]. Co-653 
administration of CBD with the A2AA-R antagonist, ZM241385, to cognitively impaired BDL mice blocked 654 
CBD-induced improvements in performance in the Eight-arm Radial Maze [55]. This blockade in performance 655 
was concurrent with reduced hippocampal TNF-α 1 receptor expression and elevated levels of BDNF expression 656 
[55]. Furthermore, ZM241385 administration had no effect on the cognitive function of Sham or BDL mice that 657 
did not receive CBD treatment [55]. The authors suggested that CBD may be an indirect agonist of A2AA-Rs 658 
[55]; indeed, another study found that CBD inhibits adenosine uptake from synaptic terminals prolonging the 659 




review investigated the influence of CBD on serotonin 5-hydroxytryptamine (5-HT) signalling in the brain in 661 
relation to cognition [54, 56]. In a model of HE that exhibited deficits in spatial learning and memory, whole 662 
brain 5-HT levels were significantly up regulated compared to controls, while acute CBD administration 663 
attenuated this increase in brain 5-HT levels [54]. In addition, 5-HT1A receptor blockade prevented CBD 664 
improvements in spatial memory in BDL mice while (paradoxically) decreasing hippocampal TNF-α 1 receptor 665 
expression, with no effect on BDNF expression [56]. Overall, these studies suggest an involvement of serotonin 666 
5-HT1A and adenosine A2A receptors in the mechanisms underlying CBD-induced improvements in cognition; 667 
however, further research is required.  668 
 669 
5 Conclusions and Future Directions  670 
In conclusion, the studies presented in the current review demonstrate that CBD has the potential to limit Δ9-671 
THC-induced cognitive impairment and improve cognitive function in various pathological conditions. Human 672 
studies suggest that CBD may have a protective role in Δ9-THC-induced cognitive impairments; however, there 673 
is limited human evidence for CBD treatment effects in pathological states (e.g. schizophrenia). Preclinical 674 
evidence suggests that overall CBD improves functioning in cognitive domains of learning and memory, in both 675 
Δ9-THC-induced and pathological states of cognitive impairment. Importantly, studies generally show no impact 676 
of CBD on cognitive function in a ‘healthy’ model, that is, outside drug-induced or pathological states. Current 677 
studies investigating drug-induced or pathological states of cognitive impairment, lack consensus on basic 678 
experimental parameters, including effective dose ranges, route of administration, frequency and duration of 679 
dosing needed to elicit optimal cognitive outcomes. In terms of schizophrenia, CBD has shown potential to treat 680 
the positive and negative symptoms of the disorder in both patients and rodent preclinical models [reviewed in 681 
24]. There is limited evidence investigating the therapeutic efficacy of CBD to treat the cognitive deficits of 682 
schizophrenia; however, CBD treatment improves cognitive function in other neurological disorders, 683 
neuropsychiatric and neuroinflammatory models of cognitive impairment. Therefore, well-designed, 684 
randomised, controlled trials conducted in schizophrenia patients will be essential to fully elucidate the potential 685 
of CBD to improve cognitive deficits in this disorder. The assessment of biochemical markers, such as 686 
circulating inflammatory (cytokines, chemokines) and oxidative stress markers, would be useful to determine 687 
the immune profiles of treated patients and whether this correlates with any CBD-induced improvements in 688 
cognition. Furthermore, future preclinical studies investigating the underlying mechanisms of action of CBD 689 




cognitive domains impaired in schizophrenia patients. In addition, the use of preclinical models of schizophrenia 691 
would assist in understanding the neurochemical signalling pathways that CBD acts upon to exert its effects on 692 
cognition function. The overall importance of this area of research is emphasized by the large percentage of 693 
patients who experience cognitive deficits, the impact on their lives and the lack of therapeutic agents currently 694 
available to treat the cognitive symptoms of schizophrenia. This justifies the need for further research to 695 
evaluate the potential of CBD as a new intervention for cognitive impairment in schizophrenia.  696 
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Figure 1: Prisma Flow Diagram for systematic research and identification of studies meeting inclusion criteria 948 
(see methods) for systematic review.  949 
75 records identified through 
database search 
3 additional records identified 
through reference lists 
40 records after duplicates 
removed 
40 records screened by title and 
abstract for eligibility 
31 full text articles assessed for 
eligibility 
27 studies included in 
qualitative synthesis 
9 articles excluded because 
they did not perform cognitive 
tests or used self-reported data 
to generate cognitive scores 
4 articles excluded because 
they did not report CBD 
content or did not have 




Table 1: Clinical studies investigating the effects of cannabidiol on cognition 
Author/Year Study Type Sample Population/Size Intervention Clinical Test Cognitive Domain Effect of CBD 





Multiple sclerosis (n=18), spinal 
cord injury (n=4), brachial plexus 
damage (n=1) and amputation (n=1) 
THC (2.5 mg), CBD (2.5 mg) or 
cannabis extract (2.5 mg 
THC+2.5 mg CBD) 










Healthy volunteers (n=20; 10M, 
10F) 
THC (10 mg), cannabis extract 
(10 mg THC+5.4 mg CBD) or 
placebo 
Choice Reaction Task processing speed, attention ≈ 
Bhattacharyya 




Healthy male volunteers (n=15) THC (10 mg), CBD (600 mg) or placebo 
Verbal memory task verbal memory 
≈ Viewing fearful faces task social recognition 
Response inhibition (Go No-Go) executive function 




Schizophrenia outpatients (n=28; 
18M, 10F) 
CBD (300 mg or 600 mg) vs 
placebo Stroop Word Colour attention ≈ 
Morgan et al. 
2010 Naturalistic study 
Cannabis users (n=134) divided into 
low (0.08%) vs. high (4.61%) CBD 
groups 
Tested in DFS and AIS (with 
participant’s chosen cannabis) 
  DFS AIS 
Prose Recall verbal memory ≈ ↑ 
Source Memory episodic memory ≈ ≈ 
Verbal category & fluency executive control ≈ ≈ 





Recreational cannabis users (n=23; 
19M, 4F) 
Nabiximols (10.8mg THC+10 mg 
CBD, 21.6 mg THC+20 mg CBD 
and 43.2 mg THC+40 mg CBD) 
or dronabinol (20 or 40 mg THC) 
Choice Reaction Time processing speed ≈ 
Divided Attention test attention ≈ 
Short-Term Memory test working memory ≈ 
Morgan et al. 
2012 Naturalistic study 
Cannabis users (n=120; 89M, 31F) 
divided into recreational (n=54) or 
daily users (n=66) 
Tested in DFS, hair samples 
analysed for cannabinoid content 
(CBD vs. no CBD) 
Prose Recall verbal memory ≈ 
Recognition memory recognition memory ↑ 
Source Memory episodic memory ≈ 





Healthy volunteers; CBD (n=22) vs. 
placebo (n=26) 
Pre-treatment with 600 mg CBD 
or placebo prior to THC 
challenge (1.5 mg) 
HVLTR verbal learning and memory ↑ 
Symbol Coding working memory ≈ 
NAB mazes executive function ≈ 
Digit Span Forward working memory ≈ 
Digit Reverse working memory ≈ 





Cannabis users (n=48; 34M, 14F), 
divided into light (n=24) and heavy 
(n=24) users 
∆9-THC (8 mg), CBD (16 mg), 
∆9-THC+CBD (8 mg +16 mg) or 
placebo 
Emotional processing task social recognition ↑∆
9-THC+CBD vs. ∆9-THC 
↑ CBD vs. placebo 
 
Abbreviations: n – number; M – male; F – female; CBD – cannabidiol; THC - tetrahydrocannabinol; HVLTR – Hopkins Verbal Learning Task Revised; DFS – drug-free state; AIS – acute intoxication state; IR – 
immediate recall; DR – delayed recall;  NAB – Neuropsychological Assessment Battery; ‘↑’ - significant improvement in cognition with CBD administration; ‘≈’ – no change in cognition with CBD administration; 




Table 2: Preclinical studies investigating the effects of cannabidiol on cognitive function 
Author/Year Sex Strain/Species Experimental Paradigm Behavioural test Cognitive domain 
CBD dose (mg/kg) 
0.5 1.0 2.0 2.5 3.0 5.0 10 12 20 30 50 60 
Lichtman et al. 
1995  
M Sprague-
Dawley rats  
Healthy rats administered cannabinoids 
(WIN-55, 212-2, CP-55, 940, anandamide, 
CBD) 
Radial arm maze  Spatial  ≈  
Hakawaya et al 
2008 
M ddY mice ∆9-THC challenge (1 mg/kg) Eight-arm maze Spatial  ≈  ≈  ↓  
Magen et al. 2009 F Sabra mice Hepatic encephalopathy via BDL Eight-arm maze Spatial  ↑  
T-maze Working  ↑  
Magen et al. 2010  F Sabra mice Hepatic encephalopathy via BDL Eight-arm maze Spatial  ↑  
Cassol-Jr et al. 2010  M Wistar rats Sepsis via CLP Inhibitory avoidance Associative  ↑  ↑ ↑  
Avraham et al. 2011  F Sabra mice Hepatic encephalopathy via TAA (200 
mg/kg) 
Eight-arm maze Spatial  ↑  
Martin-Moreno et 
al. 2011  
F/M C57Bl/6 mice Aβ intraventricular injection AD model MWM Spatial  ↑  
Barichello et al. 
2012  
M Wistar rats Meningitis model Inhibitory avoidance Associative  ≈  ≈ ↑  
Fagherazzi et al. 
2012 






 ≈ ↑  
Chronic  ↑ ↑  
Pazos et al. 2012  F/M Wistar rats Hypoxic ischaemic injury via 
electrocoagulation 
NOR Recognition  ↑  
Wright et al. 2013  M Rhesus monkey ∆9-THC challenge (0.5 mg/kg) vsPAL Declarative ↑  





Abbreviations: F – female; BDL – bile duct ligation; CBD – cannabidiol; M – male; CLP – cecal ligation and puncture; TAA – thioacetamide; AD – Alzheimer’s disease; MWM – Morris Water Maze; NOR – novel 
object recognition test; ∆9-THC - ∆9-tetrahydrocannabinol; vsPAL – visuospatial paired associate learning task; SOSS – self-ordered spatial search task; RTT – rotating turntables task; BCCAO – bilateral common 
carotid artery occlusion; PAC – paclitaxel; CM – cerebral malaria; PbA – Plasmodium berghei-ANKA; ‘↑’ - significant improvement in cognition with CBD administration; ‘≈’ – no change in cognition with CBD 





RTT Procedural ≈  
Cheng et al. 2014  M AβPPxPSI mice   AβPPxPSI double transgenic AD model NOR Recognition  ↑  
Social Preference Social recognition  ↑  
Fear Conditioning Associative  ≈  
Cheng et al. 2014  M AβPPxPSI AβPPxPSI double transgenic AD model Social Preference Social recognition  ↑  
Schiavon et al. 2014  M Swiss mice Hypoxic ischaemic injury via BCCAO MWM Spatial learning  ↑  ↑  ↑  
Ward et al 2014 F C57Bl/6 mice Healthy rats Autoshaping task Associative  ≈  ≈  ≈  
Campos et al. 2015  F C57Bl/6 mice CM via PbA + antimalarial Artesunate 
(32mg/kg) 
NOR Recognition  ↑  
MWM Spatial  ↑  
Deiana et al. 2015  M Wistar rats  MK-801 (0.08 mg/kg) model of 
schizophrenia 
Social Preference Social recognition  ≈  ≈  ≈  
Gomes et al. 2015 M C57Bl/6 mice MK-801 (1 mg/kg) model of 
schizophrenia 




Supplementary Table 1: Characteristics of studies excluded from the systematic review 
Author/Year Journal of publication Database Type of study  Study design Reason for exclusion 
da Silva et al. 
2014 [71] 
Molecular Neurobiology  Web of 
Science  
Experimental rat model 
(male Wistar rats) 
Chronic CBD administration for 14 days to rats subjected to neonatal iron 
overload as a model of neurodegenerative disorders. Western blot and real-time 
PCR analysis of brain proteins associated with mitochondrial fusion and fission 
mechanisms.  
No behavioural tests were performed 
to assess cognition.  




Scopus  Experimental rat model 
(male Sprague-Dawley 
rats) 
Acute CBD intervention via transdermal delivery vs. i.p. in rats submitted to 
alcohol-induced neurodegeneration. Assessed neuron degeneration via Fluoro-
Jade B staining methods.  
No behavioural tests were performed 
to assess cognition. 
Long et al. 
2012 [73] 
PLoS ONE Scopus Experimental mouse model 
(female C57Bl/6 mice) 
Acute and long-term CBD intervention (dose) in a Nrg1 HET mouse model of 
schizophrenia  
No behavioural tests were performed 
to assess cognition (data on NORT 
testing was not reported).  
Aragona et 
al. 2011 [74] 




group cross-over trial 
Intervention with cannabis extract Sativex (1:1 ratio of ∆9-THC: CBD) in 
cannabis-naïve MS patients (n=17). Assessed on PASAT (measures attention 
and information processing) and self-reported measures of symptoms, quality of 
life, anxiety and fatigue. 
No groups to control for ∆9-THC or 
CBD effects alone (only Sativex vs. 
placebo).  
Bergamaschi 






Drug-naïve Social Anxiety Disorder patients received either CBD (600mg) or 
placebo 1.5h prior to the SPST, vs. healthy controls (no medication). Assessed 
physiological measures and subjective scores on the VMAS and SSPS-N. 
No behavioural tests were performed 
to assess cognition. 
Lafuente et 
al.2011 [76] 
Paediatric Research Scopus Experimental newborn 
piglet model  
CBD intervention (0.1 mg/kg) 15 and 240 min post-HI induction in newborn 
piglets. Assessed neurophysiological and neurobehavioral scores and performed 
histological and biochemical analyses. 
No behavioural tests were performed 
to assess cognition.  
Winton-
Brown et al. 
2011 [77] 





Acute intervention with ∆9-THC (10 mg), CBD (600 mg) or placebo to healthy 
volunteers (n=14). Assessed cannabinoid blood levels, physiological 
parameters, psychopathology, sensory stimulation task.  
 No behavioural tests were performed 
to assess cognition. 
Juckel et al. 
2007 [78] 





Intervention with ∆9-THC alone or standardised cannabis extract (∆9-THC + 
CBD) in healthy volunteers (n=22) and assessed effects on MMN amplitudes.  
No behavioural tests were performed 
to assess cognition.  
Niyuhire et 
al. 2007 [79] 




Experimental mouse model 
(male C57BL/6 mice) 
Intervention with marijuana (50, 100 or 200 mg), ∆9-THC (1, 3 or 10 mg/kg) or 
placebo and tested in the Morris water maze (spatial learning and memory).  
Did not use standardised cannabis 




Ilan et al. 
2005 [80] 




controlled, mixed between 
and within-subjects design 
Intervention with marijuana cigarettes containing ∆9-THC (high or low) with 
CBC (high or low) and CBD (high or low) in healthy cannabis users (n=23). 
Assessed physiological measures (blood pressure, heart rate), cognitive test 
battery (word presentation, working memory and word recognition tasks), EEG 
recording.  
Use of CBC in paradigm without a 
CBD only group – cannot determine if 
effects are due to CBD.  
Wade et al. 
2004 [81] 






controlled, parallel group 
trial  
Intervention with CMBE: ∆9-THC+CBD (ratio of 1:1, 2.5 – 120mg, daily) in 
MS outpatients (n=160). Recorded VAS of symptoms, disability, mood, 
cognition, sleep and fatigue.  
 
No groups to control for ∆9-THC or 
CBD effects alone (only Sativex vs. 
placebo). 
Guy et al. 
2003 [82] 
Journal of Cannabis 
Therapeutics 
Scopus  Partially randomised, 
placebo-controlled, cross-
over trial  
Intervention with whole-plant extracts of ∆9-THC, CBD, ∆9-THC: CBD (1:1 
ratio) and placebo to assess tolerability of sublingual drops, sublingual aerosol 
or inhalation delivery methods to healthy subjects (n=6). Assessed 
pharmacokinetics and self-reported symptoms, well-being, intoxication scores, 
mood and cognition, and adverse event scores. 
No behavioural tests were performed 
to assess cognition. 
 
Leweke et al. 
2000 [83] 
Pharmacology Biochemistry 





Intervention with nabilone (1 mg) and CBD (200 mg) on binocular depth 
inversion in male human volunteers (n=9). Assessed subjective measures of 
mood, anxiety and vividness of imagery. 
No behavioural tests were performed 
to assess cognition. 
  
 
